Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study

The study population consisted of patients with a documented history of episodic (4 - 14 baseline migraine days) or chronic migraine (≥15 baseline headache days), who had been successfully randomized to clinical trial CAMG334ADE01. Key inclusion Criteria: * Signed informed consent must be obtained prior to participation in the study * Patient is capable of understanding the nature, significance and implications of the clinical trial. * Adults ≥18 years of age upon entry into screening Key exclusion Criteria: * Use of a prophylactic migraine medication within five plasma clearance half-lives, or a device or procedure within one month prior to the start of the Open-label Treatment Epoch. This exclusion criteria does not apply to erenumab or topiramate administered within clinical trial CAMG334ADE01 * Any prior exposure to (investigational) prophylactic migraine products targeting the CGRP pathway, other than erenumab.